Clinical Guidelines and Patient Selection in 2026
While widely used, viscosupplementation is not a first-line therapy. In 2026, clinical guidelines from organizations like the AAOS and the EUROVISCO group suggest that HA injections are most effective for patients with mild-to-moderate (Kellgren-Lawrence Grade 2-3) osteoarthritis who have failed to respond to physical therapy,
weight loss, or NSAIDs. It is increasingly utilized for patients who cannot take oral anti-inflammatories due to gastrointestinal or cardiovascular risks. While its use in the hip, shoulder, and ankle is considered "off-label" by many insurers, clinical evidence continues to grow for these applications, particularly when administered using ultrasound guidance to ensure precise intra-articular placement
1 vista
